Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
View Older Stories
-
Novavax Reports Fourth Quarter and Year-End 2016 Financial Results
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017
-
Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
Novavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference
-
Novavax to Participate in the Citi 2016 Global Healthcare Conference
-
Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference
-
Novavax Reports Third Quarter 2016 Financial Results
-
Novavax (NVAX) Reschedules Investor, Analyst Meeting; Wants to Finalize Resolve Trial Data
-
Novavax Reschedules 4th Annual Investor and Analyst Meeting
-
Novavax to Host 4th Annual Investor and Analyst Meeting
-
Novavax (NVAX) Reports RSV F Vaccine Phase 3 Missed Primary, Secondary Efficacy Objectives
-
Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults
-
Novavax to Host 4th Annual Investor and Analyst Meeting
-
Novavax Reports Second Quarter 2016 Financial Results
-
Novavax Recognized by Washington Post as Top Workplace
-
Novavax (NVAX) Announces Presentation of New Seasonal Influenza Nanoparticle Data at HVTD Keystone
-
Novavax Announces New Seasonal Combination Respiratory Vaccine Program
-
Novavax's (NVAX) RSV F Vaccine Granted FDA Fast-Track Designation
-
U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults
-
Novavax Receives the Tech Council of Maryland’s Chairman’s Award
-
Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day
-
Novavax Reports First Quarter 2016 Financial Results
-
Novavax to Participate in the FBR New Prescriptions Conference
-
Novavax to Present at the 15th Annual Needham Healthcare Conference
-
Novavax (NVAX) Appoints New VP of Biostatistics
-
Novavax Announces Management Promotion
-
Novavax Reports Fourth Quarter and Year-End 2015 Financial Results
-
Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs
-
Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
Novavax Appoints Mark Twyman Vice President Marketing
-
Novavax (NVAX) Announces Completion of Resolve Enrollment
-
Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
-
Novavax to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference
-
Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization
-
Novavax to Present at the 27th Annual Piper Jaffray Healthcare Conference
-
Novavax to Make Multiple Presentations at RSV Vaccines for the World
-
Novavax to Present at the Stifel 2015 Healthcare Conference
-
Novavax Reports Third Quarter 2015 Financial Results
-
Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
-
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2015
-
Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults
-
Novavax Announces Management Promotion
-
Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics
-
Novavax to Host 3rd Annual Analyst and Investor Meeting
-
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization
-
Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization
-
Novavax to Host 3rd Annual Analyst and Investor Meeting
-
Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference
-
Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model
-
Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease
